Kardigan, Inc.

Kardigan develops medicines to treat heart diseases, particularly conditions where the heart muscle weakens and fails to pump blood effectively. The company uses artificial intelligence and real-world patient data to design its drug studies and identify which patients are most likely to benefit from treatment. They acquired a platform that uses FDA-cleared technology to collect detailed information from heart patients and use it to guide their research. Kardigan licenses or buys drugs developed by other companies to add to the medicines it is developing itself.